Abiopharma

New Form 424B5 - Indaptus Therapeutics, Inc. Filed: 2025-09-02 AccNo: 0001493152-25-012530 Size: 686 KB

New Form 8-K - Savara Inc Filed: 2025-09-02 AccNo: 0001193125-25-193507 Size: 6 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 6-K - Inspira Technologies OXY B.H.N. Ltd Filed: 2025-09-02 AccNo: 0001213900-25-082964 Size: 24 KB

New Form 424B2 - Royalty Pharma plc Filed: 2025-09-02 AccNo: 0001193125-25-193500 Size: 635 KB

Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

New Form POSASR - Royalty Pharma plc Filed: 2025-09-02 AccNo: 0001193125-25-193495 Size: 303 KB

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

New Form 8-K - PULSE BIOSCIENCES, INC. Filed: 2025-09-02 AccNo: 0001437749-25-028093 Size: 167 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS

Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting

GoodRx Saddles Up With“The Savings Wrangler,” a Bold New Brand Campaign to Tame the Wild West of Prescription Pricing

- Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios

Savara Inc. - Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

New Form POS AM - Cyclacel Pharmaceuticals, Inc. Filed: 2025-09-02 AccNo: 0001641172-25-026154 Size: 273 KB

New Form 8-K - vTv Therapeutics Inc. Filed: 2025-09-02 AccNo: 0001193125-25-193486 Size: 818 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits